Global Perspectives

Although its domestic market is on the rise, Pakistan's market conditions have not proved welcoming enough to keep foreign investors.

While the world pulls itself out from one of the worst crises in decades, Indian pharmaceutical companies are trying to capitalize on falling company prices by increasing their takeovers.

With government support, China's pharmaceutical equipment sector is trekking ahead despite challenges regarding the country's overall perceived product quality.

The Indian government may soon monopolize its pharmaceutical industry to cut costs and improve healthcare, but the move is sounding off alarm bells with the companies whose drug products are under review.

Molecules called "chaperones" facilitate correct protein folding.

A recent report shows a decline in NASs and a rise in NME applications in 2007.

Although the European Union's approval rates of biosimilars for market is increasing slower than expected, its approach may provide an example for other foreign markets.

Differential pricing is making more than just an appearance in Asia's pharma market these days.

Surrounded by competition, Vietnam's 2020 vision focuses on building a biotech sector worthy of its Asian neighbors-as well as the growing global biopharmaceutical market

Drugmakers seeking to block the activity of a protein may have a new strategy at their disposal.

Staff reductions are not surprising with the state of the economy and falling pharmaceutical sales.

A growing preference for public-private partnerships is spurring innovation and technology among Dutch pharmaceutical companies.

Recent reports discuss the future of pharma's emerging markets.

With rising drug deveopment costs and burdensome clinical trials, Indian-based firms are transferring their research departments to other entities in hopes of saving cash, mitigating risk, and ultimately, buying back the rewards.

Scientists are uncovering signaling systems that operate via cannabinoid messenger molecules.

With counterfeiting on the rise and Europeans worried their backyard is becoming a base for such illegal activity, legislators have proposed a series of solutions that span the continent and abroad.

According to the latest figures from IMS Health, Inc., Japan's pharmaceutical market is expected to grow 1–2% this year compared to global industry growth expectations of 5–6%.

Although there have been recent setbacks for China with regard to exported products, the country has made substantial strides in its pharmaceutical industry over the past few years. Intense competition and a series of new regulations seem to be moving the country into a period of recovery.

Antibodies are highly specific molecules that can be tailored to recognize almost any stretch of peptide that nature can conjure: a feature that has been exploited for years now to produce therapeutic antibodies.

Sophisticated replication techniques have made counterfeiting and fraud a serious threat to the pharmaceutical industry.

A. Nair discusses patent disputes in India.

New research and ideas for March 2008

A wave of pharmaceutical expansions is expected in Europe this year, surprisingly by Indian companies.

Text sirtuins are the new kinases, according to a presentation given last month at the JP Healthcare Investors Conference in San Francisco by Sirtis CEO Christoph Westphal.

The $6.3 billion Indian pharmaceutical industry is at a crossroad. Aiming to be the international home for quality drugs, which could in itself propel India's market to $20 billion by 2015 according to recent estimates, the generic hothouse is clearly moving beyond its earlier low-cost mindset.

Indian pharmaceutical machine manufacturers (IPMMs) are exceptional among their foreign counterparts. Historically similar to the Chinese with regard to copycat practices, patent infringements, and substandard quality, the IPMMs have made great strides in innovation and collaboration to break free from the shackles of this paradigm.

The overall market size of the Southeast Asia region totals $7 billion, with a projected compound annual growth rate of about 13% through 2010.

Multinational, brand-name drug companies dominate 70% of the whole market, whereas local and generic drug companies dominate 30% of the market.